Compare Abercrombie & Fitch Co. (ANF) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abercrombie & Fitch Co. vs Zimmer Biomet Holdings Inc — how do they compare? Abercrombie & Fitch Co. trades at $114.86 (market cap $5.24B), while Zimmer Biomet Holdings Inc trades at $94.38 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 3.5× Abercrombie & Fitch Co.'s market cap, and Zimmer Biomet Holdings Inc pays a 0.99% dividend while Abercrombie & Fitch Co. pays none. Which is the better fit depends on your goals.
| ANF | ZBH | |
|---|---|---|
Market Cap | $5.24B | $18.55B |
Sector | Consumer Cyclical | Health |
52-Week High | $129.85 | $107.71 |
52-Week Low | $65.61 | $79.58 |
Enterprise Value | $5.91B | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ANF trades at $118.53, up 5.25% today, reflecting strong momentum. The stock exhibits bullish technical signals with support at $114 and resistance at $121. Fundamentally, the company reported robust earnings, with Q1 2026 EPS of $1.47 beating expectations of $1.28, and revenue growth from $4.3B in 2024 to $4.95B in 2025. Profitability metrics are solid, with a net income margin of 11.44% in 2025 and ROE of 39.04%.
Outlook is positive due to consistent earnings beats and strategic campaigns, but risks include market volatility and competitive pressures. Analysts are mixed with a consensus price target of $112.86, below the current price, suggesting potential overvaluation. Institutional interest is growing, with Amundi increasing its stake by 201.2% in Q2 2026.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
